Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar;47(3):746-752.
doi: 10.1002/jmri.25822. Epub 2017 Jul 21.

Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats

Simona Bussi  1 , Alessandra Coppo  1 , Catherine Botteron  2 , Valérie Fraimbault  2 , Antonello Fanizzi  1 , Elisa De Laurentiis  1 , Sonia Colombo Serra  1 , Miles A Kirchin  3 , Fabio Tedoldi  1 , Federico Maisano  1
Affiliations

Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats

Simona Bussi et al. J Magn Reson Imaging. 2018 Mar.

Abstract

Purpose: To compare the levels of gadolinium in the blood, cerebrum, cerebellum, liver, femur, kidneys, and skin after multiple exposure of rats to the macrocyclic gadolinium-based contrast agents (GBCAs) gadoterate, gadobutrol, and gadoteridol.

Materials and methods: Fifty male Wistar Han rats were randomized to three exposure groups (n = 15 per group) and one control group (n = 5). Animals in the exposure groups received a total of 20 GBCA administrations (four administrations per week for 5 consecutive weeks) at a dose of 0.6 mmol/kg bodyweight. After a 28-day recovery period animals were sacrificed and the blood and tissues harvested for determination of gadolinium (Gd) levels. Gd determination was performed by inductively coupled plasma mass spectrometry (ICP-MS).

Results: After 28 days' recovery no Gd was found in the blood, liver, or skin of any animal in any group. Significantly lower levels of Gd were noted with gadoteridol compared to gadoterate and gadobutrol in the cerebellum (0.150 ± 0.022 vs. 0.292 ± 0.057 and 0.287 ± 0.056 nmol/g, respectively; P < 0.001), cerebrum (0.116 ± 0.036 vs. 0.250 ± 0.032 and 0.263 ± 0.045 nmol/g, respectively; P < 0.001), and kidneys (25 ± 13 vs. 139 ± 88 [P < 0.01] and 204 ± 109 [P < 0.001], respectively). Higher levels of Gd were noted in the femur (7.48 ± 1.37 vs. 5.69 ± 1.75 and 8.60 ± 2.04 nmol/g, respectively) with significantly less Gd determined for gadoterate than for gadobutrol (P < 0.001) and gadoteridol (P < 0.05).

Conclusion: Differences exist between macrocyclic agents in terms of their propensity to accumulate in tissues. The observed differences in Gd concentration point to differences in GBCA washout rates in this setting and in this experimental model, with gadoteridol being the GBCA that is most efficiently removed from both cerebral and renal tissues.

Level of evidence: 2 Technical Efficacy: Stage 5 J. Magn. Reson. Imaging 2018;47:746-752.

Keywords: GBCA; Gd deposition; gadolinium based contrast agents; macrocyclic.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Gadolinium content (mean ± SD) in cerebellum, cerebrum, femur, and kidneys.
See this image and copyright information in PMC

References

    1. Costello JR, Kalb B, Martin DR. Incidence and risk factors for gadolinium‐based contrast agent immediate reactions. Top Magn Reson Imaging 2016;25:257–263. - PubMed
    1. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104–1108. Erratum: Nephrol Dial Transplant 2006;21:1745. - PubMed
    1. Heverhagen JT, Krombach GA, Gizewski E. Application of extracellular gadolinium‐based MRI contrast agents and the risk of nephrogenic systemic fibrosis. Rofo 2014;186:661–669. - PubMed
    1. Endrikat J, Vogtlaender K, Dohanish S, Balzer T, Breuer J. Safety of gadobutrol results from 42 clinical phase II to IV studies and postmarketing surveillance after 29 million applications. Invest Radiol 2016;51:537–543. - PMC - PubMed
    1. Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1‐weighted MR images: relationship with increasing cumulative dose of a gadolinium‐based contrast material. Radiology 2014;270:834–841. - PubMed

MeSH terms